Understanding CEACAM1 in Mantle Cell Lymphoma and New Treatments
Official title: The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma
Funded at Beckman Research Institute/city of Hope · NIH-11127607 · Data updated 2026-11-12
This research looks for new ways to treat mantle cell lymphoma, especially for patients whose current medications are not working well.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | July 1, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $401,561 |
| NIH project number | 5R01CA262754-05 |
| Project ID | NIH-11127607 on NIH RePORTER |
Who could benefit from this research
✓Could help
This foundational research is for patients with mantle cell lymphoma who are interested in the development of future treatment options, especially those facing drug resistance.
✕Less likely to help
Patients seeking immediate new treatments or direct clinical trial participation may not find direct benefit from this early-stage laboratory research.
What this research studies
Mantle cell lymphoma (MCL) is a challenging cancer where current treatments, like ibrutinib, often stop working over time. We are exploring why some MCL cells become resistant to these drugs by focusing on a specific protein called CEACAM1, which appears to be very important for MCL cells to grow. By understanding how CEACAM1 helps cancer cells, we hope to find new targets for medicines that could offer better options for patients. This work could lead to new treatments that overcome drug resistance and improve outcomes for those with MCL.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments for mantle cell lymphoma, particularly for patients who have become resistant to existing therapies.
How similar studies have gone: While the specific role of CEACAM1 in MCL is a novel focus, understanding cancer cell signaling has successfully led to effective treatments for other lymphomas.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Ngo, Vu Nguyen — Beckman Research Institute/city of Hope
- Study coordinator: Ngo, Vu Nguyen
Related research
Other NIH-funded projects on the same topics.
-
Understanding how CEACAM1 affects B-cell signaling and treatment in mantle cell lymphoma
This study is looking at a protein called CEACAM1 that might affect how certain immune cells work in people with mantle cell lymphoma, especially those who aren't responding well to treatments like ibrutinib, to find new ways to help improve their treatment options.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Immunotherapy for B-cell lymphoma using NK T cells
A patient-focused immunotherapy approach using natural killer T cells engineered to target B-cell lymphoma, potentially offering off-the-shelf treatment options.
-
Targeting MALT1 to Strengthen Anti-Lymphoma Immunity and Boost Immunotherapy
Aims to improve treatment for a common type of B-cell lymphoma by blocking a specific protein (MALT1) to enhance the body's immune attack and response to existing therapies.
-
Duvelisib for preventing cytokine release syndrome in CAR T-cell therapy patients
A study tests whether taking duvelisib before CAR T-cell therapy can prevent dangerous inflammatory reactions in patients with large B-cell or mantle cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.